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Objectives: To compare the characteristics of pregnant women with hyperglycemia according to the
severity of glucose intolerance using the 100-g oral glucose tolerance test (OGTT) and to demonstrate the
need to manage the condition of women with mild hyperglycemia.
Materials and methods: In this retrospective cohort study, a total of 258 women at high risk of gestational
diabetes (GDM) based on a positive 50-g oral glucose challenge test (OGCT) were classiﬁed into 0þ, 1þ,
2þ, 3þ, and 4þ groups according to the number of abnormal plasma glucose values on the 100-g OGTT.
The clinical characteristics of the groups were compared.
Results: The rates of advanced maternal age ( 35 years), multiparity, prior history of GDM, preterm
birth, cesarean delivery, and elevated body mass index were all positively correlated with the number of
abnormal plasma glucose values on the OGTT (p < 0.05 for all variables). After adjusting for confounding
factors, the fasting plasma glucose levels predicted birth weight in 44.4%, 48.4%, and 58.6% of the women
in the positive 50-g OGCT group, the 0þ group, and the 1þ group, respectively. Weight gain during
pregnancy predicted birth weight in 42%, 44.6%, and 37.6% of the women in the positive 50-g OGCT
group, the 0þ group, and the 2þ group, respectively (p < 0.001 in each case).
Conclusions: These data demonstrate that the detection and management of mild hyperglycemia below
the current diagnostic criteria of GDM as well as GDM diagnosed using the 100-g OGTT are necessary for
improving pregnancy outcomes.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Gestational diabetes mellitus (GDM) is deﬁned as glucose
intolerance of variable severity with onset or ﬁrst recognition
during pregnancy [1]. Fetal hyperinsulinemia secondary to
maternal hyperglycemia in diabetic mothers leads to large for
gestational age (LGA) and macrosomic infants through the stimu-
latory action of insulin on fetal growth [2]. A large multicenter,
multiethnic group study (the HAPO study) of 25,505 women who
underwent a 75-g oral glucose tolerance test (OGTT) revealed a
continuous, positive relationship among maternal glucose, fetal
insulin, and fetal growth, including LGA infants and neonatal
adiposity [3,4]. Therefore, fetal hyperinsulinemia in women withf Korea, Department of Ob-
, 271, Cheonbo-ro, Uijeongbu-
).
bstetrics & Gynecology. PublishedGDM and womenwith hyperglycemia below the diagnostic criteria
for GDM may result in increased birth weight and neonatal
adiposity through the stimulatory action of insulin. The data from
several studies have supported the results of the HAPO study [5,6].
Maternal hyperglycemia that is below the diagnostic criteria for
GDM is associated with an increased risk of various adverse
maternal and infant outcomes, such as cesarean delivery, pre-
eclampsia, birth injury, macrosomia, and neonatal hypoglycemia
[3,5e7]. Fortunately, several clinicians have reported that man-
aging GDM and hyperglycemia that is below the diagnostic criteria
for GDM has improved maternal and infant outcomes [8e10].
Therefore, it is necessary to detect and manage maternal hyper-
glycemia regardless of severity. However, there is no consensus
regarding the criteria for screening and diagnosing GDM. Addi-
tionally, the management of hyperglycemia below the diagnostic
criteria for GDM is not routinely recommended. It is difﬁcult to
identify critical blood glucose values for diagnosing GDM, including
hyperglycemia of any severity, and to achieve cost-effective
management.by Elsevier Taiwan LLC. All rights reserved.
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women with hyperglycemia according to the severity of glucose
intolerance using the 100-g OGTT, and we aimed to demonstrate
the necessity of managing women with hyperglycemia that falls
below the diagnostic criteria for GDM.
Materials and methods
The medical records of 300 pregnant women who underwent a
100-g OGTT after a positive 50-g oral glucose challenge test (OGCT)
and delivered at Uijeongbu St. Mary's Hospital from January 2006
to August 2012 were retrospectively reviewed. Our hospital uses a
two-step (screening followed by diagnostic) approach for GDM, as
recommended by the American Diabetes Association [11]. Brieﬂy,
we perform a 50-g nonfasting OGCT at 24e28 weeks of gestation. If
the 1-hour plasma glucose level is > 140 mg/dL, a 100-g OGTT is
performed, and plasma glucose levels are measured in the fasting
state and at 1 hour, 2 hours, and 3 hours after ingestion of the
glucose load. A diagnosis of GDM is made if two or more plasma
glucose levels are above the thresholds established by Carpenter
and Coustan [12] in 1982, namely fasting  95 mg/dL, 1 hour 
180 mg/dL, 2 hours  155 mg/dL, and 3 hours  140 mg/dL. He-
moglobin A1c level is not part of the diagnostic criteria. In our
hospital, women who are diagnosed with GDM undergo consulta-
tions regarding nutrition and are encouraged to exercise. Insulin
therapy is typically initiated if a fasting glucose < 95 mg/dL or a 2-
hour postprandial plasma glucose < 120 mg/dL is not consistently
maintained by dietary management.
Women with multiple pregnancies, pregestational diabetes
mellitus, or non-Korean ethnicity, and who received insulin ther-
apy for GDM or registered at our hospital after the ﬁrst trimester,
were excluded from the analysis. Therefore, the medical records of
258 pregnant women who were eligible for this study were
reviewed. The eligible pregnant women were classiﬁed into the
0þ group (n ¼ 93, 36.0%), the 1þ group (n ¼ 38, 14.7%), the 2þ
group (n¼ 54, 20.9%), the 3þ group (n¼ 47, 18.2%), or the 4þ group
(n ¼ 26, 10.1%) according to the number of abnormal plasma
glucose values that met or exceeded the threshold levels of the 100-
g OGTT. The maternal baseline characteristics, the glucose values in
the 50-g OGCT, the glucose values in the 100-g OGTT (fasting, 1-
hour, 2-hour, and 3-hour), prepregnancy body mass index (BMI),
BMI at the time of the 50-g OGCT, BMI at delivery, weight gain prior
to the 50-g OGCT, weight gain during pregnancy, and birth weight
were compared among the groups. In all of the women, weight was
measured at each visit throughout the pregnancy, and height was
measured at the ﬁrst antenatal care visit. BMI was calculated as
body mass (kg) divided by the square of height (m2) and classiﬁed
as < 18.5 kg/m2, 18.5e24.9 kg/m2, 25e29.9 kg/m2, or  30 kg/m2.
Prepregnancy BMI was calculated using the baseline weight (self-
reported prepregnancy weight or weight measured at the ﬁrst visit
during early pregnancy when the prepregnancy weight was un-
known) and measured height. Weight gain prior to the 50-g OGCT
was calculated as the difference between the baseline weight and
the weight at the time of the 50-g OGCT. Weight gain during
pregnancy was calculated as the baseline weight subtracted from
the weight at admission for delivery. Gestational weight gain was
recorded both as absolute weight gain in grams and as weight gain
categories, as deﬁned by the 2009 Institute of Medicine (IOM)
recommendations based on an individual patient's prepregnancy
BMI: 12.5e18.0 kg for underweight women with a BMI < 18.5 kg/
m2, 11.5e16.0 kg for normal weight women with a BMI of
18.5e24.9 kg/m2, 7.0e11.5 kg for overweight women with a BMI of
25.0e29.9 kg/m2, and 5.0e9.0 kg for obese women with a
BMI  30 kg/m2 [13]. Birth weight was recorded both as absolute
weight (in grams) and as birth weight categories: small forgestational age (SGA; < 10th percentile), appropriate for gestational
age (AGA; 10the90th percentile), LGA (> 90th percentile), and
macrosomia (estimated fetal weight  4000 g). This study was
approved by the Institutional Review Board of Uijeongbu St Mary's
Hospital at The Catholic University in Seoul, Korea.
All analyses were performed using the SAS 9.2 software (SAS
Institute, Cary, NC, USA). Data are expressed as either the
mean ± standard deviation for continuous variables with a normal
distribution or the median and interquartile range for variables
with non-normal distributions. Categorical variables are expressed
as numbers and percentages. For analysis of the differences in
continuous variables among the groups, data were analyzed using
one-way analysis of variance (ANOVA) followed by the post hoc
Duncan's test for parametric data and the KruskaleWallis test fol-
lowed by the post hoc Dunn's test for nonparametric data. Analysis
of trends in categorical variables was performed using the Chi-
square test and the CochraneManteleHaenszel test with adjust-
ment for confounding factors. Spearman's correlation coefﬁcient
was used to evaluate the correlations between several variables and
birth weight. Multiple linear regression modeling with adjustment
for confounding variables was used for the birth weight prediction
analysis. A p value < 0.05 was used to indicate statistical
signiﬁcance.
Results
The mean age of the women studied was 33.8 ± 4.1 years
(Table 1). Women in the 2þ and 4þ groups were similar in age and
older than those in the other three groups. Maternal age < 35 years,
primiparity, and vaginal delivery were associated with fewer
abnormal OGTT results, whereas maternal age  35 years, multi-
parity, a prior pregnancy complicated by GDM, preterm birth, and
cesarean delivery were associated with a higher number of
abnormal OGTT results (Table 1). The gestational age at birth in the
4þ group was 37 weeks (range, 34e39 weeks), which was signiﬁ-
cantly shorter than that in the other four groups (p ¼ 0.0024). The
plasma glucose values on the 50-g OGCTwere similar in the 1þ, 2þ,
and 3þ groups, but together they were signiﬁcantly higher than
those in the 0þ group and signiﬁcantly lower than those in the 4þ
group (Table 1).
After adjusting for confounding factors (including maternal age,
parity, history of prior GDM, and gestational age at birth), pre-
pregnancy BMI was higher in the 4þ group than in the 0þ and 3þ
groups (p ¼ 0.031), and BMI at the time of the 50-g OGCT was
higher in the 2þ and 4þ groups than in the 0þ group (p ¼ 0.027).
After adjusting for confounding factors, prepregnancy BMI, BMI at
the time of the 50-g OGCT, and BMI at delivery were all positively
correlated with the number of abnormal plasma glucose values on
the OGTT (Table 2).
After adjusting for confounding factors (including maternal age,
parity, history of prior GDM, gestational age at birth, and pre-
pregnancy BMI), fasting plasma glucose values were similar in the
1þ, 2þ, and 3þ groups but were together signiﬁcantly higher than
those in the 0þ group and signiﬁcantly lower than those in the 4þ
group (Table 3). Both the 1-hour and 2-hour OGTT plasma glucose
levels were noted to increase signiﬁcantly with increasing numbers
of abnormal OGTT results (i.e., from the 0þ group through the 4þ
group). This observation also held for the 3-hour OGTT plasma
glucose levels, however, the difference in 3-hour plasma glucose
levels between the 2þ and 3þ groups failed to reach statistical
signiﬁcance (Table 3).
Overall, women gained a total of 6.0 kg (median, range
4.4e8.4 kg) of weight prior to their 50-g OGCT and 11.4 kg
(8.5e14.4 kg) throughout their pregnancy. Weight gain prior to the
50-g OGCT and gestational weight gain were not signiﬁcantly
Table 1
Clinical characteristics of the study population according to the number of abnormal plasma glucose values in the 100-g oral glucose tolerance test (OGTT).
All women (n ¼ 258) 100-g OGTT p
0þ 1þ 2þ 3þ 4þ
(n ¼ 93, 36.0%) (n ¼ 38, 4.7%) (n ¼ 54, 20.9%) (n ¼ 47, 18.2%) (n ¼ 26, 10.1%)
Age (y) 33.8 ± 4.1 32.8 ± 3.5 33.6 ± 4.0 35.8 ± 4.2 33.4 ± 4.6 34.3 ± 4.1 0.001a,b,c,d,e,f
< 35, n (%) 152 (58.9) 66 (71.0) 25 (65.8) 18 (33.3) 30 (63.8) 13 (50.0) 0.000
 35, n (%) 106 (41.1) 27 (29.0) 13 (34.2) 36 (66.7) 17 (36.2) 13 (50.0)
Parity, n (%)
Primipara 115 (44.6) 48 (51.6) 20 (52.6) 18 (33.3) 23 (48.9) 6 (23.1) 0.028
Multipara 143 (55.4) 45 (48.4) 18 (47.4) 36 (66.7) 24 (51.1) 20 (76.9)
Prior history of
GDM, n (%)
46 (17.8) 1 (1.1) 1 (2.6) 15 (27.8) 17 (36.2) 12 (46.2) <0.000a,b,d,g,f,h,i
Gestational age
at birth (wk)
38.0 (37.0e39.0) 38.0 (38.0e39.0) 38.0 (38.0e40.0) 38.0 (37.0e39.0) 38.0 (37.0e39.0) 37.0 (36.0e38.0) 0.002b,d,f,g
Preterm birth,
n (%)
38 (14.7) 7 (7.5) 5 (13.2) 7 (13.0) 11 (23.4) 8 (30.8) 0.016
Delivery method,
n (%)
Normal labor 123 (47.7) 59 (63.4) 16 (42.1) 21 (38.9) 17 (36.2) 10 (38.5) 0.005
Cesarean 135 (52.3) 34 (36.6) 22 (57.9) 33 (61.1) 30 (63.8) 16 (61.5)
Indication for cesarean, n (%)
Previous
cesarean
59 (44.0) 12 (35.3) 13 (59.1) 17 (53.1) 10 (33.3) 7 (43.8) 0.236
Others 75 (56.0) 22 (64.7) 9 (40.9) 15 (46.9) 20 (66.7) 9 (56.3)
50-g OGTT
(mg/dL)
157.5 (147.0e172.0) 151.0 (144.0e160.0) 160.0 (148.0e173.0) 158.0 (146.0e171.0) 157.0 (148.0e172.0) 199.5 (176.0e236.0) < 0.001a,b,d,g,f,h
Data are presented as the mean ± standard deviation, median (interquartile range), or n (%); p value for the differences among 0þ versus 1þ versus 2þ versus 3þ versus 4þ
using one-way analysis of variance (ANOVA) or the Chi-square test for age; p value for the differences among 0þ versus 1þ versus 2þ versus 3þ versus 4þ using the
KruskaleWallis test or Chi-square test for other variables; p value for the difference between: (a) 0þ versus 2þ; (b) 0þ versus 4þ; (c) 1þ versus 2þ; (d) 1þ versus 4þ; (e) 2þ
versus 3þ; (f) 3þ versus 4þ; (g) 2þ versus 4þ; (h) 0þ versus 1þ; (i) 0þ versus 3þ by multiple comparisons using one-way ANOVA, followed by the post-hoc Duncan's test, or
the KruskaleWallis test, followed by the post hoc Dunn's test.
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were expressed in terms of absolute weight gain or weight gain
above, within, or below the IOM recommendations (data not
shown).
The birth weight of newborns in the study population was
3260 g (median, range, 2900e3510 g). The overall rates of SGA,
AGA, LGA, and macrosomia were 8.1%, 83.4%, 8.5%, and 5.4%,
respectively. Absolute birth weight, macrosomia, and the distri-
bution of SGA, AGA, and LGAwere not signiﬁcantly different among
the various study groups (data not shown).Table 2
Comparison of body mass index (BMI) according to the number of abnormal plasma glu
All women (n ¼ 258)
0þ 1þ
(n ¼ 93, 36.0%) (n ¼ 38, 14
Prepregnancy BMI (kg/m2) 22.8 (20.1e26.3) 20.9 (19.6e23.7) 22.4 (19.8e
< 18.5, n (%) 20 (7.8) 12 (12.9) 3 (7.9)
18.5e24.9, n (%) 161 (62.4) 63 (67.7) 25 (65.8)
25e29.9, n (%) 53 (20.5) 12 (12.9) 6 (15.8)
 30, n (%) 24 (9.3) 6 (6.5) 4 (10.5)
BMI at the time of 50-g
OGCT (kg/m2)
25.6 (22.8e29.2) 23.4 (21.3e26.2) 25.2 (23.0e
< 18.5, n (%) d d d
18.5e24.9, n (%) 114 (44.2) 60 (64.5) 19 (50.0)
25e29.9, n (%) 90 (34.9) 21 (22.6) 10 (26.3)
 30, n (%) 54 (20.9) 12 (12.9) 9 (23.7)
BMI at delivery (kg/m2) 27.4 (24.9e31.2) 25.6 (23.9e29.2) 26.9 (24.8e
<18.5, n (%) d d d
18.5e24.9, n (%) 68 (26.4) 39 (41.9) 10 (26.3)
25e29.9, n (%) 112 (43.4) 33 (35.5) 16 (42.1)
 30, n (%) 78 (30.2) 21 (22.6) 12 (31.6)
Data are presented as the median (interquartile range) or n (%); data were adjusted for ma
for the differences among 0þ versus 1þ versus 2þ versus 3þ versus 4þ using the Kruskal
4þ; (b) 3þ versus 4þ; (c) 0þ versus 2þ bymultiple comparisons using the KruskaleWallis
for parity; (f) adjusted for previous gestational diabetes history; (g) adjusted for gestatioFasting plasma glucose levels were positively correlated with
birth weight in the positive 50-g OGCT group (all women studied),
the 0þ group, and the 1þ group.Weight gain during pregnancywas
positively correlated with birth weight in the positive 50-g OGCT
group, the 0þ group, and the 2þ group. However, birth weight was
not correlated with the 1-hour, 2-hour, and 3-hour OGTT plasma
glucose values, prepregnancy BMI, BMI at the time of the 50-g
OGCT, weight gain prior to the 50-g OGCT, or weight gain above
the IOM recommendations (data not shown). To identify factors
within this high-risk cohort that were independently correlatedcose values in the 100-g oral glucose tolerance test (OGTT).
100-g OGTT Adjusted p
2þ 3þ 4þ
.7%) (n ¼ 54, 20.9%) (n ¼ 47, 18.2%) (n ¼ 26, 10.1%)
25.0) 24.4 (21.9e26.8) 22.4 (19.9e26.8) 24.7 (24.0e28.4) 0.031a,b
3 (5.6) 2 (4.3) 0 (0.0) 0.006d
29 (53.7) 30 (63.8) 14 (53.9) 0.009e
17 (31.5) 10 (21.3) 8 (30.8) 0.035f
5 (9.3) 5 (10.6) 4 (15.4) 0.001g
27.9) 27.6 (24.8e29.8) 25.6 (23.2e29.6) 27.1 (25.9e31.0) 0.027a,c
d d d <0.000d
14 (25.9) 19 (40.4) 2 (7.7) <0.000e
27 (50.0) 18 (38.3) 14 (53.9) 0.000f
13 (24.1) 10 (21.3) 10 (38.5) <0.000g
31.2) 28.7 (26.6e31.6) 27.3 (25.0e31.2) 28.4 (27.5e32.8) 0.183
d d d 0.002d
8 (14.8) 11 (23.4) 0 (0.0) 0.002e
24 (44.4) 23 (48.9) 16 (61.5) 0.012f
22 (40.7) 13 (27.7) 10 (38.5) 0.000g
ternal age, parity, previous gestational diabetes, and gestational age at birth; p value
eWallis test or the Chi-square test; p value for the differences among: (a) 0þ versus
test, followed by the post-hocDunn's test; (d) adjusted for maternal age; (e) adjusted
nal age at birth.
Table 3
Comparison of individual plasma glucose levels according to the number of abnormal plasma glucose values in the 100-g oral glucose tolerance test (OGTT).
All women (n ¼ 258) 100-g OGTT Adjusted p
0þ 1þ 2þ 3þ 4þ
(n ¼ 93, 36.0%) (n ¼ 38, 14.7%) (n ¼ 54, 20.9%) (n ¼ 47, 18.2%) (n ¼ 26, 10.1%)
Fasting
glucose
(mg/dL)
86.0 (81.0e95.0) 81.0 (78.0e85.0) 89.0 (82.0e96.0) 86.0 (81.0e91.0) 92.0 (83.0e101.0) 124.0 (104.0e154.0) < 0.001a,b,c,d,e,f
1-h glucose
(mg/dL)
171.0 (144.0e198.0) 139.0 (124.0e153.0) 165.0 (159.0e175.0) 185.5 (169.0e196.0) 201.0 (182.0e220.0) 246.0 (229.0e283.0) < 0.001j
2-h glucose
(mg/dL)
154.0 (131.0e178.0) 125.0 (109.0e139.0) 147.0 (137.0e159.0) 166.5 (158.0e179.0) 181.0 (169.0e202.0) 222.5 (195.0e269.0) < 0.001j
3-h glucose
(mg/dL)
126.0 (107.0e147.0) 107.0 (95.0e118.0) 125.5 (112.0e136.0) 128.5 (118.0e146.0) 150.0 (142.0e164.0) 205.5 (159.0e257.0) < 0.001a,b,c,d,e,f,g,h,i
Data are presented as the median (interquartile range); data were adjusted for maternal age, parity, previous gestational diabetes, gestational age at birth, and prepregnancy
body mass index; p value for the differences among 0þ versus 1þ versus 2þ versus 3þ versus 4þ using the KruskaleWallis test; p value for the differences among: (a)
0þ versus 1þ; (b) 0þ versus 2þ; (c) 0þ versus 3þ; (d) 0þ versus 4þ; (e) 1þ versus 4þ; (f) 2þ versus 4þ; (g) 3þ versus 4þ; (h) 1þ versus 2þ; (i) 1þ versus 3þ; (j) 0þ versus 1þ
versus 2þ versus 3þ versus 4þ by multiple comparisons using the KruskaleWallis test, followed by the post hoc Dunn's test.
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analysis, adjusting for maternal age, parity, history of prior GDM,
gestational age at birth, and prepregnancy BMI. The results showed
that the following factors were independently predictive of birth
weight in the cohort: (1) fasting plasma glucose levels in the pos-
itive 50-g OGCT group (44.4%); (2) fasting plasma glucose levels in
the 0þ group (48.4%); (3) weight gain during pregnancy in the
positive 50-g OGCT group (42%); and (4) weight gain during preg-
nancy in the 2þ group (37.6%; Table 4). Fasting plasma glucose
levels in the 1þ group and weight gain during pregnancy in the
0þ group were signiﬁcantly correlated with birth weight. However,
these variables were able to predict birth weight only after
adjusting for confounding factors in the multiple regressionmodels
(fasting plasma glucose levels in 58.6% of the women in the 1þ
group and weight gain during pregnancy in 44.6% of the women in
the 0þ group; Table 4).
Discussion
A recent study reported that age > 35 years and history of GDM
were the greatest risk factors for GDM [14]. In this study, weTable 4
Multivariate linear regression analysis of factors affecting birth weight.
Multivariatea
Parameter
estimate (b)
Standard
error
p for b Adjusted R2 p
All women
Fasting glucose
(mg/dL)
0.219 0.049 < 0.001 0.444 < 0.001
Weight gain
during pregnancy
(kg)
0.036 0.017 0.033 0.420 < 0.001
0þ group
Fasting glucose
(mg/dL)
0.528 0.205 0.012 0.484 < 0.001
Weight gain
during pregnancy
(kg)
0.012 0.027 0.663 0.446 < 0.001
1þ group
Fasting glucose
(mg/dL)
0.206 0.158 0.202 0.586 < 0.001
2þ group
Weight gain
during pregnancy
(kg)
0.129 0.041 0.003 0.376 < 0.001
a Adjusted for maternal age, parity, previous gestational diabetes, gestational age
at birth, and prepregnancy body mass index.demonstrated that these and other known GDM risk factors were
correlated with maternal hyperglycemia. This ﬁnding suggests that
risk factors for GDM are also risk factors for maternal hyperglyce-
mia that falls below the diagnostic criteria for GDM. Several clini-
cians have reported that the cesarean delivery rate is higher among
women with GDM compared with nondiabetic women and among
women with borderline GDM compared with normoglycemic
controls [15,16]. Additionally, they reported that the recognition of
GDM or borderline GDM may lower the threshold for cesarean
delivery, and there were no differences in the indications for ce-
sarean delivery in women with GDM compared with nondiabetic
women [15,16]. Our data support these reports by demonstrating
that the cesarean delivery rate was correlated with the severity of
maternal hyperglycemia without affecting the indications for ce-
sarean delivery. In addition, our data demonstrated that gestational
age at birth was lower in the 4þ group than in the other groups due
to increased preterm birth rates according to the increased severity
of maternal hyperglycemia.
Prepregnancy BMI has recently been reported as a predictor of
GDM and is signiﬁcantly associated with maternal hyperglycemia
[17,18]. In this study, the prepregnancy BMI values and the BMI
values at the time of the 50-g OGCT in the women in the 2þ and 4þ
groups whowere diagnosedwith GDMwere signiﬁcantly increased
compared with those in the 0þ group, which supports the current
diagnostic criteria for GDM. However, the BMI values in the women
in the 3þ group who were diagnosed with GDM were similar to
those in the 0þ and 1þ groups, suggesting that the current diag-
nostic criteria for GDM must be extended because of the lack of
differences between the groups that fell below the diagnostic
criteria for GDM and the GDM groups. In addition, this study
demonstrated that higher BMIs ( 25 kg/m2) in the prepregnancy
stage, at the time of the 50-g OGCT, and at delivery were correlated
with the severity of maternal hyperglycemia, which suggests that a
higher BMI ( 25 kg/m2) is a risk factor for maternal hyperglycemia.
Our data demonstrate that compared with the other groups, the
glucose values in the 50-g OGCT and the fasting plasma glucose
values were the lowest in the 0þ group and the highest in the 4þ
group; these values were similar among the 1þ, 2þ, and 3þ groups.
These results suggest the need to extend the current diagnostic
criteria for GDM because of the lack of differences between the
groups that fell below the diagnostic criteria for GDM and the GDM
groups.
A recent study reported that a signiﬁcant decrease in weight
gain during pregnancy was correlated with the severity of maternal
hyperglycemia based on a two-step approach in the diagnosis of
GDM [18]. Another recent study of 1145 women reported that the
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gain prior to the 50-g OGCT, particularly during the ﬁrst trimester
[19]. However, in contrast to these studies, our data demonstrated
that weight gain prior to the 50-g OGCT and weight gain during
pregnancy were not correlated with an increase in maternal hy-
perglycemia. A retrospective study of 31,074 women who were
diagnosed with GDM reported that the group with a weight gain
that exceeded the IOM recommendations (31.7%) had a higher risk
of LGA ormacrosomic infants and that the groupwith aweight gain
that fell below the recommendations (35.2%) was more likely to
have SGA infants when compared with the group with a weight
gain that met the recommendations (33.1%) [20]. Studies have re-
ported that the risk of macrosomia increases linearly according to
the increase in the 50-g OGCT and 100-g OGTT values and that the
incidence of LGA and macrosomic infants is increased in women
with only three abnormal 100-g OGTT values [6,21]. However, for
the women with a positive 50-g OGCT in this study, we observed a
greater prevalence of patients with a weight gain that was below
(38.8%) or within (40.7%) the IOM recommendations and a lower
prevalence of patients with a weight gain that was above (20.5%)
the recommendations compared with the previous study.
Furthermore, these ﬁndings were not correlated with the severity
of maternal hyperglycemia on the 100-g OGTT. Therefore, the
absence of differences in birth weight and the distribution of SGA,
AGA, LGA, and macrosomic infants according to the severity of
maternal hyperglycemia on the 100-g OGTT may be explained by
the similar weight gain prior to the 50-g OGCT, the similar weight
gain during pregnancy, and the similar distribution of the sub-
groups that exceeded, were within, and fell below the IOM rec-
ommendations among the groups. In addition, our data
demonstrated that the weight gain during pregnancy (11.4 kg) was
similar to the weight gain (8e15 kg) reported in previous studies
and that the rates of LGA (3.9%) andmacrosomic (5.4%) infants were
markedly lower than the rates (10e40%) reported in previous
studies. Moreover, the birth weight (3260 g) of the infants in this
study was similar to that in previous studies, and the rate of SGA
(8.1%) infants was higher than the rates in previous studies
[6,21e23]. Therefore, the greater prevalence of women with a
weight gain that fell below or within the IOM recommendations
and the lower prevalence of women with a weight gain that
exceeded the recommendationsmay partially explain themarkedly
low rates of LGA and macrosomic infants and the high rate of SGA
infants in this study. Maternal fasting plasma glucose levels are
associated with an increased risk of neonatal adiposity or macro-
somia in pregnant womenwith or without GDM [5,24e26]. A study
that assessed a cohort of 89,141 womenwithout GDM reported that
fasting plasma glucose levels obtained at the 100-g OGTT were
associated with the highest risk of LGA infants [25]. Therefore, the
markedly low rates of LGA and macrosomic infants in this study
may also be partially explained by the presence of a fasting plasma
glucose level higher than the diagnostic threshold for GDM only in
the 4þ group.
Interestingly, our data demonstrated that the fasting plasma
glucose levels at the OGTT predicted birth weight only in pregnant
women with hyperglycemia that was below the diagnostic criteria
for GDM, not in women with GDM. This ﬁnding strongly suggests
that it is necessary to detect and manage maternal hyperglycemia
that falls below the diagnostic criteria for GDM as well as GDM.
Weight gain during pregnancy may be associated with an increased
risk of macrosomia in pregnant women with GDM [6,20,22]. No
differences were observed in weight gain during pregnancy or in
birth weight among the groups in this study; however, the weight
gain during pregnancy in the 0þ and 2þ groups predicted birth
weight, which suggests the possible inﬂuence of other factors.
Additionally, our results demonstrated that fasting plasma glucoselevels and weight gain during pregnancy predicted birth weight,
which suggests that these parameters could be monitored in
women who undergo only the 50-g OGCT and not the 100-g OGTT.
In conclusion, similar to previous studies, we demonstrated a
signiﬁcant increase in multiple GDM risk factors and adverse
pregnancy outcomes in association with the severity of maternal
hyperglycemia, as detected by the 100-g OGTT. Speciﬁcally, we
showed that fasting plasma glucose levels at the OGTT and gesta-
tional weight gain were independent predictors of birth weight.
Our data also demonstrated that the fasting plasma glucose levels
in women with mild hyperglycemia that fell below the diagnostic
criteria for GDM were more closely associated with birth weight
when these women without intervention were compared with
patients with GDM who received a consultation regarding diet and
exercise. Finally, these data suggest the need to extend the current
diagnostic criteria for GDM to include women in the 0þ and 1þ
groups based on the 100-g OGTT. When women are newly diag-
nosed with GDM according to extended criteria, advised on diet
and exercise, and monitored with respect to their plasma glucose
levels, adverse maternal and infant outcomes could be improved
with minimal increases in health care costs. Further large-scale
studies should continue to develop new diagnostic criteria for
GDM, including mild hyperglycemia, to improve pregnancy
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